Kardigan priced its IPO at $16 per share for 25 million shares, aiming to raise about $400 million. The deal includes a 30-day option for underwriters to buy up to 3.75 million additional shares. Trading on Nasdaq Global Market under KARD is expected to begin June 18, 2026, with closing on June 22, 2026, providing runway for cardiovascular programs.
Kardigan disclosed plans for a US initial public offering with a target valuation of up to $1.4 billion. The release provides no pricing or timing details, but signals a potential funding catalyst for the company. If the IPO proceeds attract strong demand, KARD could see near-term upside; dilution risk and market conditions remain key watch points.
